Imugene Ltd has released a press release.
Appendix 4C - Quarterly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- FDA ind approval of new oncolytic virotherapy checkvacc
- Investor Presentation
- Prestigious Research Journal Publish HER-Vaxx Phase 1B Data
- Appendix 4C - quarterly
- Imugene announces clinical milestone for HER-Vaxx
Later from Imugene
- Imugene completes $90 M placement and launches $5 M SPP
- Prospectus for SPP and Placement Options Offer
- Research partnership with Celularity for solid tumors
- Response to ASX Query
- Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene